These results advocate for combination regimens with drugs exhibiting distinct mechanisms of action, e.g. concurrent chemotherapy with immunotherapy or anti-PD-1 plus anti-CTLA-4 [85] to eradicate cancer cells displaying different immunogenomic features to improve survival of patients with synchronous lung cancer metastases [66]. Here, CTLA4 is linked to lung cancer.